BlackRock
EUCR

BlackRock’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

BlackRock’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-899,823
Closed -$9.02M – 5885
2022
Q3 		$9.02M Sell
899,823
-309
-0% -$3.08K ﹤0.01% 3480
2022
Q2 		$8.9M Hold
900,132
– – ﹤0.01% 3564
2022
Q1 		$8.86M Hold
900,132
– – ﹤0.01% 3642
2021
Q4 		$8.79M Sell
900,132
-24,868
-3% -$244K ﹤0.01% 3756
2021
Q3 		$9.05M Hold
925,000
– – ﹤0.01% 3715
2021
Q2 		$9.11M Hold
925,000
– – ﹤0.01% 3672
2021
Q1 		$9.23M Buy
+925,000
New +$9.5M ﹤0.01% 3621

Other funds holding EUCR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock's EUCR Position: Q4 2022 in Review

BlackRock sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 899,823 shares — an estimated $9.02M sold.

BlackRock first reported a position in EUCR in Q1 2021 and held it in 7 quarters. The position peaked at $9.23M in Q1 2021. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

  • BlackRock reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 899,823 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $9.02M.
  • BlackRock first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 7 quarters.
  • BlackRock's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $9.23M in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.